Everolimus

Generic Name
Everolimus
Brand Names
Afinitor, Votubia, Zortress
Drug Type
Small Molecule
Chemical Formula
C53H83NO14
CAS Number
159351-69-6
Unique Ingredient Identifier
9HW64Q8G6G
Background

Everolimus is a derivative of Rapamycin (sirolimus), and works similarly to Rapamycin as an mTOR (mammalian target of rapamycin) inhibitor. It is currently used as an immunosuppressant to prevent rejection of organ transplants. In a similar fashion to other mTOR inhibitors Everolimus' effect is solely on the mTORC1 protein and not on the mTORC2 protein.

Indication

Everolimus is indicated for the treatment of postmenopausal women with advanced hormone receptor-positive, HER2-negative breast cancer (advanced HR+ BC) in combination with exemestane, after failure of treatment with letrozole or anastrozole.
...

Associated Conditions
Heart Transplant Rejection, Kidney Transplant Rejection, Liver Transplant Rejection, Progressive Neuroendocrine Tumors of pancreatic origin, Renal angiomyolipoma, tuberous sclerosis complex, Subependymal giant cell astrocytoma, tuberous sclerosis complex, Waldenstrom's Macroglobulinemia Refractory, Advanced Carcinoid tumor, Locally advanced Progressive Neuroendocrine Tumors of gastrointestinal origin, Locally advanced lung origin Progressive Neuroendocrine Tumors, Metastatic gastrointestinal origin Progressive Neuroendocrine Tumors, Metastatic lung origin Progressive Neuroendocrine Tumors, Refractory Advanced Renal Cell Carcinoma, Refractory, advanced Breast cancer, Unresectable gastrointestinal origin Progressive Neuroendocrine Tumors, Unresectable lung origin Progressive Neuroendocrine Tumors
Associated Therapies
-

RAD001 Plus Bevacizumab in Metastatic Melanoma

Phase 2
Completed
Conditions
Interventions
First Posted Date
2008-01-11
Last Posted Date
2021-11-24
Lead Sponsor
SCRI Development Innovations, LLC
Target Recruit Count
57
Registration Number
NCT00591734
Locations
🇺🇸

Watson Clinic Center for Cancer Care and Research, Lakeland, Florida, United States

🇺🇸

Oncology Hematology Associates of SW Indiana, Evansville, Indiana, United States

🇺🇸

Florida Hospital Cancer Institute, Orlando, Florida, United States

and more 12 locations

Efficacy of Everolimus as Inhibitor of Fibrosis Progression in Liver Transplant Patients With Recurrence of Hepatitis C Viral Infection

First Posted Date
2007-12-28
Last Posted Date
2012-09-06
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
43
Registration Number
NCT00582738
Locations
🇦🇷

Novartis Investigative site, Buenos Aires, Argentina

Study of Combined Fulvestrant and Everolimus in Advanced/Metastatic Breast Cancer After Aromatase Inhibitor Failure

Phase 2
Completed
Conditions
Interventions
First Posted Date
2007-12-11
Last Posted Date
2017-02-23
Lead Sponsor
Mara Chambers
Target Recruit Count
33
Registration Number
NCT00570921
Locations
🇺🇸

University of Kentucky, Lexington, Kentucky, United States

Treatment of Patients Suffering From a Progressive Pancreas Carcinoma With Everolimus (RAD001) and Gemcitabine

First Posted Date
2007-11-20
Last Posted Date
2020-12-21
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
21
Registration Number
NCT00560963
Locations
🇩🇪

Novartis Investigative Site, Ulm, Germany

Everolimus, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma

First Posted Date
2007-11-04
Last Posted Date
2020-02-13
Lead Sponsor
Alliance for Clinical Trials in Oncology
Target Recruit Count
122
Registration Number
NCT00553150
Locations
🇺🇸

Park Nicollet Cancer Center, Saint Louis Park, Minnesota, United States

🇺🇸

Mayo Clinic Scottsdale, Scottsdale, Arizona, United States

🇺🇸

Mayo Clinic - Jacksonville, Jacksonville, Florida, United States

and more 173 locations

Everolimus, Cytarabine, and Daunorubicin in Treating Patients With Relapsed Acute Myeloid Leukemia

Phase 1
Conditions
First Posted Date
2007-10-16
Last Posted Date
2013-09-17
Lead Sponsor
Institut de Recherche Clinique sur les Cancers et le Sang
Target Recruit Count
21
Registration Number
NCT00544999
Locations
🇫🇷

Hopital Cochin, Paris, France

Everolimus in Treating Patients With Newly Diagnosed Localized Prostate Cancer

First Posted Date
2007-09-10
Last Posted Date
2018-12-06
Lead Sponsor
Jorge A. Garcia, MD
Target Recruit Count
17
Registration Number
NCT00526591
Locations
🇺🇸

Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States

Temozolomide and Everolimus in Treating Patients With Stage IV Melanoma That Cannot be Removed by Surgery

Phase 2
Completed
Conditions
Interventions
First Posted Date
2007-08-27
Last Posted Date
2017-08-14
Lead Sponsor
Alliance for Clinical Trials in Oncology
Target Recruit Count
49
Registration Number
NCT00521001
Locations
🇺🇸

Meeker County Memorial Hospital, Litchfield, Minnesota, United States

🇺🇸

St. Mary - Corwin Regional Medical Center, Pueblo, Colorado, United States

🇺🇸

Memorial Hospital, Carthage, Illinois, United States

and more 192 locations

Efficacy and Safety of Everolimus (RAD001) in Patients With Advanced Gastric Cancer

Phase 2
Completed
Conditions
Interventions
First Posted Date
2007-08-22
Last Posted Date
2016-11-18
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
54
Registration Number
NCT00519324
Locations
🇯🇵

Novartis Investigative Site, Tochigi, Japan

🇯🇵

Novartis investigative Site, Tokyo, Japan

Everolimus in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma

Phase 2
Completed
Conditions
Interventions
First Posted Date
2007-08-15
Last Posted Date
2015-09-29
Lead Sponsor
Swiss Group for Clinical Cancer Research
Target Recruit Count
35
Registration Number
NCT00516412
Locations
🇨🇭

Kantonsspital Winterthur, Winterthur, Switzerland

🇨🇭

Klinik Hirslanden, Zurich, Switzerland

🇨🇭

Universitaetsspital-Basel, Basel, Switzerland

and more 18 locations
© Copyright 2024. All Rights Reserved by MedPath